Fortitude Family Office’s Immunovant IMVT Stock Holding History

Fortitude Family Office’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-21	Closed	-$885	–	1035
2023 Q4	$885	Buy	+21	New	+$773	﹤0.01%	951

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Fortitude Family Office's IMVT Position: Q1 2024 in Review

Fortitude Family Office sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 21 shares — an estimated $885 sold.

Fortitude Family Office first reported a position in IMVT in Q4 2023 and held it in 1 quarter. The position peaked at $885 in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

Fortitude Family Office reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
Fortitude Family Office sold 21 Immunovant shares in Q1 2024, an estimated $885.
Fortitude Family Office first reported a position in Immunovant in Q4 2023 and held it in 1 quarter.
Fortitude Family Office's Immunovant position peaked at $885 in Q4 2023.
209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Fortitude Family Office's 13F filing for Q1 2024, filed 11 Apr 2024.